Background: The aim of this study was to determine whether enteral self-expanding metal stent (SEMS) placement or gastrojejunostomy (GJY) for palliation of malignant gastric outlet obstruction (GOO) symptoms results in better survival and quality-of-life outcomes.
Introduction
Gastric outlet obstruction (GOO) can result from either a benign or malignant etiology. Benign GOO etiologies include ulcer-or radiation-induced strictures. More commonly, GOO occurs in a malignant setting; pancreatic cancer is the most common, and others include gastric, duodenal, and hepatocellular cancers, lymphoma, and metastatic cancers. Depending on the etiology and/or origin of the primary cancer, GOO can occur at the distal stomach, pylorus, or duodenum. Patients with malignant GOO suffer from intractable nausea, vomiting, abdominal pain and distension, and intolerance to an oral diet. This worsens the nutritional state of these patients, who are already debilitated due to cancer-related cachexia. Palliation of such symptoms is of utmost importance for such patients, not only to improve their debilitated state but also to enable them to enjoy eating during their terminal days.
Techniques currently available for palliation of malignant GOO include surgical procedures such as gastrojejunostomy (GJY) and endoscopic placement of a duodenal self-expanding metal stent (SEMS). GJY was the standard treatment to relieve malignant GOO prior to the introduction of SEMS. It provides symptom relief in most patients, but is associated with significant immediate postprocedure morbidity and delayed gastric emptying. The introduction of endoscopic placement of a duodenal SEMS provided an alternative with faster symptom relief and much lower postprocedure morbidity. However, recurrent obstructive symptoms and the need for reintervention are considered to be significant drawbacks of duodenal SEMS.
Several studies, including three randomized controlled trials, [1] [2] [3] one prospective study, 4 and some retrospective studies, [5] [6] [7] [8] [9] [10] [11] [12] [13] have compared the outcomes for GJY and duodenal SEMS. The results of these studies have also been summarized in systematic reviews and a meta-analysis. [14] [15] [16] However, all of those studies had small sample sizes. Therefore, we performed a retrospective study to compare the outcomes for large groups of patients who underwent GJY or endoscopic SEMS placement for palliation of malignant GOO symptoms at a tertiary care cancer center during the last 10 years.
Methods

Study design and patient population
In this retrospective cohort study, we included patients with GOO due to unresectable cancer who underwent GJY or enteral SEMS placement between 2001 and 2011. Patients with malignant GOO symptoms who underwent GJY to cure the underlying malignancy were not included in the study. We reviewed patients' medical records for demographic data, the type of cancer causing the GOO, pre-procedure World Health Organization (WHO) performance status score, history of chemo-and radiotherapy, and type of procedure.
Outcomes
Patients with GOO were classified into GJY and enteral SEMS groups. The outcomes compared between the two groups were as follows: (1) number of days to tolerance of a liquid diet and then a mechanical soft diet; (2) rate of recurrence of obstructive symptoms; (3) rate of reintervention; (4) duration of hospital stay; (5) complication rate; and (6) survival rate and duration. We also compared the rate of biliary obstruction and the need for biliary intervention before or after GJY or SEMS placement. To compare survival data, the date of death was noted for patients. Data for patients who were lost to follow-up were censored on the date of the last follow-up.
Statistical analysis
Categorical variables are presented as frequency and the corresponding percentage. Continuous variables are summarized using descriptive statistics including the mean and standard deviation or the median and range. We used Fisher's exact test and the Wilcoxon rank sum test to compare the baseline characteristics and procedure-related outcomes for the SEMS and GJY groups. A value of P < 0.05 was considered statistically significant. The Kaplan-Meier method was used to estimate overall survival and recurrence-free survival. The log-rank test and Cox regression analysis were used to determine prognostic factors for overall survival and recurrencefree survival. Variables for which P < 0.15 were included in the multivariate analysis. SAS software version 9.3 (SAS Institute, Cary, NC, USA) and TIBCO Sportfire S-Plus software version 8.2 (TIBCO Software, Palo Alto, CA, USA) were used for analyses.
Results
The baseline characteristics of the 334 patients who underwent GJY (n ¼ 93, 27.8%) or SEMS placement (n ¼ 241, 72.2%) are presented in Table 1 . The proportion of patients who had a baseline WHO performance status score ! 2 was significantly higher in the SEMS group (93/146 patients for whom data were available, 63.7%) than in the GJY group (8/23 patients for whom data were available, 34.7%; P ¼ 0.012). The proportion of patients who received preprocedure chemo-or radiotherapy was significantly higher in the SEMS group (168/241 patients, 69.6%) than in the GJY group (46/93 patients, 49.5%; P ¼ 0.0009). The numbers of patients who underwent SEMS placement or GJY per year during the study period are shown in Fig. 1 . Overall, more patients underwent SEMS placement than GJY for palliation of malignant GOO symptoms.
Oral intake toleration, length of hospital stay, and weight gain
Oral intake was tolerated by 204/241 patients (84.6%) in the SEMS group and 79/93 patients (84.9%) in the GJY group. There was no significant difference between the groups for ability to tolerate a liquid diet (P ¼ 0.593) or a soft diet (P ¼ 0.881). The mean times to liquid diet and soft diet tolerance were significantly shorter in the SEMS group (2.2 AE 3.9 days and 4.8 AE 6.2 days, respectively) than in the GJY group (8.9 AE 5.6 days and 13.6 AE 20.3 days, respectively; P ¼ 0.0001; Table 2 ). Patients who underwent GJY had a significantly longer hospital stay than patients who underwent SEMS did (P < 0.0001). The difference in weight gain between the groups at 30 and 60 days was not significant (P ¼ 0.472 and 0.973, respectively).
Complications
The types of complication experienced by the patients in the two groups are presented in Table 3 . The overall complication rate was significantly higher in the GJY group (10/93 patients, 10.8%) than in the SEMS group (11/241 patients, 4.5%; P ¼ 0.045). Some patients in the GJY group experienced severe medical complications including sepsis, postoperative renal failure, and aspiration pneumonia. No patients in the SEMS group had any severe medical complications.
Recurrence of symptoms
Recurrence of obstructive symptoms occurred in 33 patients in the SEMS group and six patients in the GJY group (P ¼ 0.086). The proportion of patients who required additional interventions for recurrent obstructive symptoms or stent-related complications was significantly higher in the SEMS group (36/241 patients, 14.9%) than in the GJY group (3/93 patients, 3.2%; P ¼ 0.002). Of the 36 patients in the SEMS group who required additional interventions, 19 underwent repeat SEMS placement, six underwent percutaneous endoscopic gastrostomy tube placement, eight underwent repeat upper endoscopy, and three underwent GJY. All three patients in the GJY group who required additional intervention underwent percutaneous endoscopic gastrostomy tube placement.
Survival
The median overall survival estimated for all patients was 3.59 months (95% confidence interval [CI] 2.83-4.24 months). The median follow-up time for surviving patients was 3.19 months (first quartile 0.7 months, third quartile 13.17 months). In the SEMS group, 209/241 patients died, with a median overall survival time of 2.4 months (95% CI 2.11-3.06 months). In the GJY group, 59/93 patients died, with a median overall survival time of 10.59 months (95% CI 7.47-16.84 months). The difference in overall survival between the groups was significant (P < 0.0001). A log-rank test showed that a good WHO performance score (e.g., <2; P ¼ 0.003), ability to tolerate a liquid diet (P < 0.0001), ability to tolerate a soft diet (P < 0.0001), and post-procedure chemo-and radiotherapy (P < 0.0001) were associated with longer overall survival, whereas the occurrence of complications was associated with shorter overall survival (P ¼ 0.029). After adjusting for gender effects, WHO performance status score, complications, and ability to tolerate any diet, multivariate analysis revealed that procedure type, the occurrence of complications, and post-procedure chemo-or radiotherapy were independent prognostic factors for overall survival (Table 4) .
We anticipated that the study would be subject to selection bias because patients with poor performance status are less likely to undergo GJY. In addition, performance status scores were missing for many patients. Hence, we compared overall survival between patients who underwent chemo-or radiotherapy after stent placement and patients who underwent GJY with or without adjuvant therapy. The underlying assumption here was that the patients undergoing chemo-or radiotherapy after stent placement would have a performance score comparable to that for patients in the GJY group. The median overall survival estimated was 10.59 months (95% CI 7.47-16.84 months) for patients who underwent GJY, 5.07 months (95% CI 3.75-7.07 months) for patients who underwent SEMS placement followed by chemo-and radiotherapy, and 1.71 months (95% CI 1.48-2.17 months) for patients who underwent SEMS placement only (P < 0.0001; Fig. 2 ). Univariate Cox proportional hazards model analysis revealed that patients undergoing SEMS placement only had the highest risk of death compared to the other two groups [hazard ratio (HR) ¼ 4.65, P < 0.0001 and HR ¼ 2.37, P < 0.0001]. Patients who received chemo-and radiotherapy after SEMS placement also had a higher risk of death compared to GJY patients (HR ¼ 1.95, P ¼ 0.0002).
The median recurrence-free survival time estimated was 2.17 months (95% CI 1.78-2.57 months) for SEMS patients and 10.59 months (95% CI 7.07-16.41 months) for GJY patients. A log-rank test revealed that a good WHO performance score (e.g., >2; P ¼ 0.004), Data are presented as n (%) or mean AE SD. the ability to tolerate any diet (P ¼ 0.001), and post-procedure chemo-or radiotherapy (P < 0.0001) were associated with longer recurrence-free survival. After adjusting for the effects of gender, performance status score, race, pre-procedure chemo-and radiotherapy, complications, and the ability to tolerate any diet, multivariate analysis revealed that procedure type (HR ¼ 0.203; P < 0.0001) and post-procedure chemo-or radiotherapy (HR ¼ 0.56; P ¼ 0.002) were independent prognostic factors for recurrence-free survival (Table 4) .
Biliary obstruction
The rate of biliary obstruction was significantly higher in the SEMS group (133/241 patients, 55.2%) than in the GJY group (32/93 patients, 34.4%; P ¼ 0.0009). This difference was probably related to selection bias, because patients with a higher tumor burden are likely to develop simultaneous biliary obstruction and less likely to undergo GJY. In the SEMS group, 55 patients underwent endoscopic biliary drainage, 50 patients had percutaneous biliary drainage, 22 patients had both endoscopic stent placement and percutaneous biliary drainage, and six patients had no biliary intervention. In the GJYgroup, 19 patients underwent endoscopic biliary drainage, four patients had percutaneous biliary drainage, and nine patients had no intervention.
Discussion
To date, this study is the largest single-center study comparing outcomes between enteral SEMS placement and GJY for palliation of malignant GOO symptoms. We found that patients who underwent SEMS placement tended to start tolerating oral intake sooner, had fewer complications, and a shorter hospital stay, but had a higher risk of recurrent obstructive symptoms compared to patients who underwent GJY. The patients who underwent GJY survived for longer than patients who underwent SEMS placement did. As discussed previously, this was most likely due to selection bias. Patients who have advanced disease and poor performance status are more likely to undergo SEMS placement.
We compared body weight but found no significant difference between the two groups. Nor did we find any significant weight gain within the groups. There are multiple reasons for this trend. Although many of the patients who underwent these procedures were able to tolerate a liquid or soft diet, they could not maintain their nutritional requirements for protein and calorie intake. In addition, all patients in the study had unresectable cancer and cancer-related cachexia, which hampers weight gain. Thus, weight gain could not be used as an outcome for comparison of the two groups and was not the goal of palliation in these patients. One of the main objectives in palliating the symptoms of GOO is to enable patients to enjoy food during their terminal days.
We found that SEMS placement has been used more frequently than GJY at our center in recent years to palliate the symptoms of malignant GOO. The upsurge in this nonsurgical procedure at our institution may be because of the increasing availability of cancer care in the community. Many patients who present to our tertiary care cancer center have already been treated at other facilities and have exhausted most options for care. By the time these patients are evaluated in our center, many have a poor performance status score, which eliminates surgical options.
A total of 48% of our GOO patients presented with a concomitant biliary obstruction. Many groups have reported their experience with methods to relieve simultaneous biliary obstruction. Combined placement of biliary and enteral SEMS can be challenging but is an effective palliative technique. [17] [18] [19] [20] [21] [22] [23] In our practice, we try to Jeurnink et al proposed that the anticipated survival time should be considered when deciding between GJY and SEMS placement for palliation of malignant GOO. 3, 15 In our study, the median recurrence-free survival in SEMS patients was 2.17 months. In general, however, predicting patient survival is difficult. Whether a patient undergoes SEMS placement or GJY depends on the performance status, the presence of comorbid conditions predicting the likelihood of an uneventful postoperative recovery, and the feasibility of GJY in a patient whose tumor has altered the surrounding anatomy. We recommend that patients with good performance statusdpatients for whom surgery is an optiondundergo GJY for palliation of malignant GOO. Our study had the inherent limitations of any retrospective study. WHO performance status scores were not available for all patients. Because our study included only patients from a tertiary cancer center, who tend to be sicker and have more advanced disease than patients in the community do, the study results may not be generalizable to patients in the community. However, our study provides data from the largest group of patients with malignant GOO who underwent SEMS placement or GJY.
In conclusion, we found that compared to GJY, SEMS placement for palliation of malignant GOO is associated with a faster time to tolerance of oral intake, fewer complications, and a shorter hospital stay, but a higher rate of recurrent symptoms of obstruction. Therefore, patients with an advanced malignancy and a short life expectancy should undergo duodenal SEMS placement for palliation of the symptoms of malignant GOO.
